* All percentage calculations set forth herein assume that there are 21,836,010 shares of Common Stock outstanding, as reported in Kohlberg Capital Corporation’s most recent Form 10-Q, filed with the Securities and Exchange Commission on August 10, 2009.
(1) See Item 2(a).
| | |
CUSIP No. 500233101
| 13D | Page 10 of 25 pages
|
| |
ITEM 1. | Security and Issuer. |
This Schedule 13D relates to the common stock, par value $0.001 per share (the “Common Stock”), of Kohlberg Capital Corporation, a corporation organized under the laws of the state of Delaware (the “Issuer”), with its principal executive offices located at 295 Madison Avenue, 6th Floor, New York, NY 10017. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable.
| |
ITEM 2. | Identity and Background. |
(a) This Schedule 13D is being filed by Cyrus Capital Partners, L.P., a Delaware limited partnership (“Cyrus”), Cyrus Opportunities Master Fund II, Ltd., a Cayman Islands company (“COMF”), CRS Fund, Ltd., a Cayman Islands company (“CRS”), Crescent 1, L.P., a Delaware limited partnership (“Crescent”), Cyrus Capital Advisors, L.L.C., a Delaware limited liability company (“Cyrus Advisors”), Cyrus Select Opportunities Master Fund, Ltd., a Cayman Islands company (“CSOMF”), Cyrus Capital Partners GP, L.L.C., a Delaware limited liability company (“Cyrus GP”), and Mr. Stephen C. Freidheim (each of Cyrus, COMF, CRS, Crescent, Cyrus Advisors, CSOMF, Cyrus GP and Mr. Freidheim, collectively, the “Reporting Persons”).
Each of COMF, CRS, Crescent and CSOMF (collectively, the “Investors”) are private investment funds engaged in the business of acquiring, holding and disposing of investments in various companies. Cyrus is the investment manager of each of the Investors. Cyrus GP is the general partner of Cyrus. Cyrus Advisors is the general partner of Crescent. Mr. Freidheim is the managing member of each of Cyrus GP and Cyrus Advisors, and the Chief Investment Officer of Cyrus.
Except for Mr. Freidheim, each Reporting Person disclaims beneficial ownership of all shares of Common Stock, other than those reported herein as being owned by such Reporting Person.
Mr. Freidheim disclaims beneficial ownership of the securities of the Issuer held by the Investors, except to the extent of his pecuniary interest in the Investors, if any.
(b) The business address of each of the foregoing Reporting Persons is 399 Park Avenue, 39th Floor, New York, New York 10022.
(c) Set forth inExhibit 1 attached hereto are the respective names, business addresses, present principal occupations and citizenships of the executive officers, directors and control persons, as applicable, of each of the Reporting Persons.
(d) During the last five years, none of the Reporting Persons has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
(e) During the last five years, none of the Reporting Persons was a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
(f) Mr. Freidheim is a citizen of the United States.
| |
ITEM 3. | Source and Amount of Funds or Other Consideration. |
The aggregate purchase price of the 1,099,887 shares of Common Stock beneficially owned by the Reporting Persons was $4,861,731.97, inclusive of brokerage commissions.
The aggregate purchase price of the 538,945 shares of Common Stock beneficially owned by COMF was $2,382,877.29, inclusive of brokerage commissions.
The aggregate purchase price of the 230,976 shares of Common Stock beneficially owned by CRS was $1,020,336.07, inclusive of brokerage commissions.
The aggregate purchase price of the 219,977 shares of Common Stock beneficially owned by Crescent was $972,345.41, inclusive of brokerage commissions.
The aggregate purchase price of the 109,989 shares of Common Stock beneficially owned by CSOMF was $486,173.20, inclusive of brokerage commissions.
Limited partners of the shareholders of each of COMF, CRS and CSOMF provided all of the funds used to purchase their respective shares of Common Stock of the Issuer. The limited partners of Crescent provided all of the funds used to purchase its shares of Common Stock of the Issuer.
| | |
CUSIP No. 500233101
| 13D | Page 11 of 25 pages
|
| |
ITEM 4. | Purpose of Transaction. |
The Reporting Persons purchased the shares of Common Stock reported herein based on the Reporting Persons’ belief that the shares of Common Stock of the Issuer at current market prices are undervalued and represent an attractive investment opportunity. Depending upon overall market and general economic conditions, other investment opportunities available to the Reporting Persons, the market prices of the shares of Common Stock of the Issuer (the “Securities”), the business affairs and financial condition of the Issuer and other factors deemed relevant to the Reporting Persons, the Reporting Persons may endeavor to increase or decrease their position in the Issuer through, among other things, the purchase or sale of Securities in the open market or in private transactions, including the purchase of Securities through a tender offer or otherwise, on such terms and at such times as the Reporting Persons may deem advisable.
On March 26, 2010, Cyrus sent a letter to the board of directors of the Issuer (the “March 26th Letter”). A copy of the March 26th Letter is attached hereto asExhibit 2 and is incorporated herein by reference. It is anticipated that the Reporting Persons may, from time to time, have discussions with management, the board of directors, and other stockholders of the Issuer. The Reporting Persons intend to monitor and evaluate the Issuer’s business, corporate governance and financial performance, to monitor efforts by management to increase stockholder value and to be available to management to the extent that the Issuer may benefit from the institutional experience of the Reporting Persons. The Reporting Persons also may seek in the future to have one or more representatives appointed or elected to the board of directors of the Issuer or to propose other matters for consideration and approval by the Issuer’s stockholders or board of directors. The Reporting Persons also may decide in the future to propose a transaction whereby all or a portion of the Issuer be sold, and in connection therewith the Reporting Persons may seek to participate in such transaction or seek to acquire control of the Issuer in a negotiated transaction or otherwise. If it or its affiliates should acquire control of the Issuer, it or its affiliates may transfer all or part of the Issuer to affiliated or unaffiliated persons.
Except as otherwise set forth herein, the Reporting Persons do not have any present plans or proposals which would relate to or result in the matters set forth in subparagraphs (a) – (j) of Item 4 of Schedule 13D.
| |
ITEM 5. | Interest in Securities of the Issuer. |
(a) The Reporting Persons beneficially own 1,099,887 shares of Common Stock, which represent approximately 5.0% of the issued and outstanding shares of Common Stock.
(b) The Reporting Persons have the power to vote, or direct the vote, and dispose of, or direct the disposition of, 1,099,887 shares of Common Stock, which represent approximately 5.0% of the outstanding shares of Common Stock.
(c) During the past 60 days, the Reporting Person have purchased 1,099,887 shares Common Stock of the Issuer.
COMF, CRS, Crescent and CSOMF acquired their respective shares of Common Stock of the Issuer on the dates and at the prices set forth onExhibit 3.
All of the shares referenced above were acquired by the Investors in the open market.
(d) No other person is known by any Reporting Person to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Common Stock beneficially owned by any Reporting Person.
(e) Not applicable.
| |
ITEM 6. | Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer. |
Not applicable.
| | |
CUSIP No. 500233101
| 13D | Page 12 of 25 pages
|
| |
ITEM 7. | Materials to be Filed as Exhibits. |
| |
Exhibit 1: | Officers and Directors of Cyrus, COMF, Crescent, Cyrus Advisors, CRS, CSOMF and Cyrus GP. |
|
Exhibit 2 | Letter dated March 26, 2010, from Cyrus to the board of directors of the Issuer. |
|
Exhibit 3 | Item 5(c) Disclosures |
|
Exhibit 4 | Joint Filing Agreement as required by Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended. |
| | |
CUSIP No. 500233101
| 13D | Page 13 of 25 pages
|
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, each of the undersigned hereby certifies that the information set forth in this statement is true, complete and correct.
EXECUTED as a sealed instrument this 26th day of March, 2010.
| | |
| CYRUS CAPITAL PARTNERS, L.P. |
| By: Cyrus Capital Partners GP, L.L.C., its general partner |
| | |
| By: | /s/ Stephen C. Freidheim |
| Name: Stephen C. Freidheim |
| Title: Managing Member |
| | |
| CYRUS CAPITAL PARTNERS GP, L.L.C. |
| | |
| By: | /s/ Stephen C. Freidheim |
| Name: Stephen C. Freidheim |
| Title: Managing Member |
| | |
| /s/ Stephen C. Freidheim |
| Stephen C. Freidheim, an individual |
| | |
| CRESCENT 1, L.P. |
| By: Cyrus Capital Advisors, L.L.C., its general partner |
| | |
| By: | /s/ Stephen C. Freidheim |
| Name: Stephen C. Freidheim |
| Title: Managing Member |
| | |
| CYRUS CAPITAL ADVISORS, L.L.C. |
| | |
| By: | /s/ Stephen C. Freidheim |
| Name: Stephen C. Freidheim |
| Title: Managing Member |
| | |
CUSIP No. 500233101
| 13D | Page 14 of 25 pages
|
| | |
| CYRUS OPPORTUNITIES MASTER FUND II, LTD. |
| | |
| By: | /s/ Stephen C. Freidheim |
| Name: Stephen C. Freidheim |
| Title: Authorized signatory |
| | |
| CRS FUND, LTD. |
| | |
| By: | /s/ Stephen C. Freidheim |
| Name: Stephen C. Freidheim |
| Title: Authorized signatory |
| |
| CYRUS SPECIAL OPPORTUNITIES MASTER FUND, LTD. |
| | |
| By: | /s/ Stephen C. Freidheim |
| Name: Stephen C. Freidheim |
| Title: Authorized signatory |
| | |
CUSIP No. 500233101
| 13D | Page 15 of 25 pages
|
EXHIBIT INDEX
| |
Exhibit 1: | Officers and Directors of Cyrus, COMF, Crescent, Cyrus Advisors, CRS, CSOMF and Cyrus GP. |
| |
Exhibit 2 | Letter dated March 26, 2010, from Cyrus to the board of directors of the Issuer. |
| |
Exhibit 3 | Item 5(c) Disclosures |
| |
Exhibit 4 | Joint Filing Agreement as required by Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended. |